Besifloxacin is the Hydrochloride salt form of Besifloxacin a broad-spectrum, fourth-generation, 8-chloro-fluoroquinolone antibiotic agent. Besifloxacin Hydrochloride is the commercially available form developed by SSP Co Ltd, Japan. It is active against both Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is primarily used against bacteria causing bacterial conjunctivitis. Besifloxacin stops the production of pro-inflammatory cytokines in vitro.
